Skip to content
Open access

From Valve Disease to Valve Replacement: Lipoprotein(a) Is Associated with Aortic Stenosis Severity but Not Prognosis After TAVI

Aug 2026 · Medical Science · Vol 14, pp. 484 · 0 citations · 29 references
Medicine

TL;DR

Elevated Lp(a) concentrations were associated with greater anatomical and hemodynamic severity of AS but not with long-term mortality after TAVI, suggesting that elevated Lp(a) is associated with greater anatomical and hemodynamic severity of calcific aortic valve disease but was not linked to long-term mortality after TAVI.

Abstract

Background: Lipoprotein(a) [Lp(a)] has emerged as a key mediator of calcific aortic valve disease and is strongly linked to the development and progression of aortic stenosis (AS). Whether elevated Lp(a) influences disease severity, long-term prognosis, or both in patients undergoing transcatheter aortic valve implantation (TAVI) remains uncertain. Methods: This multicenter study included 213 patients with severe symptomatic AS undergoing TAVI between 2016 and 2018. Pre-procedural Lp(a) concentrations were measured using a standardized immunoturbidimetric assay. Associations with long-term all-cause mortality were evaluated using Kaplan–Meier analyses and Cox proportional hazards models. The relationship between Lp(a) and AS severity was assessed using correlation analyses, multivariable linear regression models, and restricted cubic spline analyses. Anatomical and hemodynamic measures included aortic valve calcium score (AVCS), peak aortic jet velocity (AV Vmax), and transvalvular pressure gradients. Results: During a median follow-up of 7.58 years (IQR 4.33–8.66 years), Lp(a) was not associated with all-cause mortality, irrespective of whether it was analyzed as a continuous variable, according to established clinical thresholds, or across quartiles. In contrast, higher Lp(a) concentrations were associated with greater valvular calcification and more severe hemodynamic obstruction. These associations remained significant after adjustment for age, sex, diabetes mellitus, and renal function. Restricted cubic spline analyses suggested predominantly linear associations without evidence of significant non-linearity. Conclusions: Elevated Lp(a) concentrations were associated with greater anatomical and hemodynamic severity of AS but not with long-term mortality after TAVI. These findings suggest that elevated Lp(a) is associated with greater anatomical and hemodynamic severity of calcific aortic valve disease but was not linked to long-term mortality after TAVI.

Read PDF

Similar papers

Review Sep 2026

Association between lipoprotein(a) and structural degeneration of bioprosthetic aortic valves: A systematic review and meta-analysis.

BACKGROUND Structural valve degeneration (SVD) remains a major limitation of bioprosthetic aortic valves (bAVs). Lipoprotein(a) [Lp(a)] is a genetically determined cardiovascular risk factor implicated in native aortic valve calcification, but its role in bioprosthetic valve degeneration remains incompletely understood...

Ermilo Echeverría-Ortegón, M. Torres-Chávez, Alfredo Perez Tagle Tejeda et al. · 0 citations
Sep 2026

Mitral Regurgitation and Severe Aortic Stenosis: Clinical Characteristics, Prognostic Impact, and Response to TAVR: Insights From Egnite Data.

Patients with concurrent MR and AS exhibit substantially higher mortality yet have high rates of undertreatment throughout the duration of follow-up, and TAVR alone significantly improves MR in most patients.

Benjamin E. Peterson, Philippe Généreaux, Pinak B. Shah et al. · 0 citations
Review Open access Aug 2026

Lipoprotein(a) and Aortic Stenosis: From Genetic Risk to Emerging Therapeutic Strategies

Experimental and translational data suggest that lipoprotein(a) exerts its effects early in the disease course, promoting valve inflammation and calcification before significant stenosis develops, raising the possibility that early lipoprotein(a)-lowering may modify disease progression, a hypothesis now being tested in...

L. Tokgozoglu, M. Kayıkçıoğlu · 0 citations
Open access Oct 2026

Early Structural Valve Deterioration After TAVR and Potential Association With Long-Term Corticosteroid Therapy: A Case Report

Early structural valve deterioration (SVD) after transcatheter aortic valve replacement (TAVR) for aortic stenosis is uncommon, particularly within 5 years post-implantation. The impact of long-term corticosteroid therapy on transcatheter bioprosthetic valve durability remains poorly understood. An 80-year...

Shiori Fuse, T. Sekimoto, Taka-aki Matsuyama et al. · 0 citations
Aug 2026

Phenotype-specific mitral regurgitation trajectories following transcatheter aortic valve replacement in low-flow aortic stenosis.

OBJECTIVES Mitral regurgitation (MR) evolution after transcatheter aortic valve replacement (TAVR) in low-flow aortic stenosis (LFAS) is poorly characterized. The authors evaluated MR trajectories across LFAS phenotypes, predictors of MR worsening, and associations with clinical outcomes. METHODS The authors retrospe...

Akarsh Sharma, E. Vaish, E. Galvani et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.